Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.
A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.
Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.